Literature DB >> 23237718

Positive and negative affect, depression, and cognitive processes in the Cognition in the Study of Tamoxifen and Raloxifene (Co-STAR) Trial.

Suzanne C Danhauer1, Claudine Legault, Hanna Bandos, Kelley Kidwell, Joseph Costantino, Leslie Vaughan, Nancy E Avis, Steve Rapp, Laura H Coker, Michelle Naughton, Cecile Naylor, Antonio Terracciano, Sally Shumaker.   

Abstract

OBJECTIVES: This study examined the relationship between positive and negative affect, depressive symptoms, and cognitive performance.
METHODS: The sample consisted of 1479 non-demented, postmenopausal women (mean age = 67 years) at increased risk of breast cancer enrolled in the National Surgical Adjuvant Breast and Bowel Project's Study of Tamoxifen and Raloxifene. At each annual visit, women completed a standardized neuropsychological battery and self-report measures of affect and depression. Data from three visits were used in linear mixed models for repeated measures using likelihood ratio tests. Separate analyses were performed to relate positive/negative affect and depression to each cognitive measure.
RESULTS: Higher positive affect was associated with better letter fluency (p = .006) and category fluency (p < .0001). Higher negative affect was associated with worse global cognitive function (p < .0001), verbal memory (CVLT List B; p = .002), and spatial ability (p < .0001). Depressive symptoms were negatively associated with verbal knowledge (p = .004), figural memory (p < .0001), and verbal memory (p's ≤ .0001). DISCUSSION: Findings are consistent with some prior research demonstrating a link between positive affect and increased verbal fluency and between depressive symptoms and decreased memory. The most novel finding shows that negative affect is related to decreased global cognition and visuospatial ability. Overall, this research in a large, longitudinal sample supports the notion that positive affect is related to increases and negative affect to decreases in performance on distinct cognitive measures.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23237718      PMCID: PMC3815441          DOI: 10.1080/13825585.2012.747671

Source DB:  PubMed          Journal:  Neuropsychol Dev Cogn B Aging Neuropsychol Cogn        ISSN: 1382-5585


  55 in total

1.  Positive mood and executive function: evidence from stroop and fluency tasks.

Authors:  Louise H Phillips; Rebecca Bull; Ewan Adams; Lisa Fraser
Journal:  Emotion       Date:  2002-03

2.  Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial.

Authors:  Victor G Vogel; Joseph P Costantino; D Lawrence Wickerham; Walter M Cronin; Reena S Cecchini; James N Atkins; Therese B Bevers; Louis Fehrenbacher; Eduardo R Pajon; James L Wade; André Robidoux; Richard G Margolese; Joan James; Scott M Lippman; Carolyn D Runowicz; Patricia A Ganz; Steven E Reis; Worta McCaskill-Stevens; Leslie G Ford; V Craig Jordan; Norman Wolmark
Journal:  JAMA       Date:  2006-06-05       Impact factor: 56.272

3.  Positive affect increases the breadth of attentional selection.

Authors:  G Rowe; J B Hirsh; A K Anderson
Journal:  Proc Natl Acad Sci U S A       Date:  2006-12-20       Impact factor: 11.205

4.  Differential age trajectories of positive and negative affect: further evidence from the Berlin Aging Study.

Authors:  Ute Kunzmann
Journal:  J Gerontol B Psychol Sci Soc Sci       Date:  2008-09       Impact factor: 4.077

5.  Personality traits prospectively predict verbal fluency in a lifespan sample.

Authors:  Angelina R Sutin; Antonio Terracciano; Melissa H Kitner-Triolo; Manuela Uda; David Schlessinger; Alan B Zonderman
Journal:  Psychol Aging       Date:  2011-06-27

6.  The relationship between psychological dimensions of depressive symptoms and cognitive functioning in the elderly - the MEMO-Study.

Authors:  Bernhard T Baune; Thomas Suslow; Volker Arolt; Klaus Berger
Journal:  J Psychiatr Res       Date:  2006-08-02       Impact factor: 4.791

7.  Are individual differences in rates of aging greater at older ages?

Authors:  Timothy A Salthouse
Journal:  Neurobiol Aging       Date:  2011-11-21       Impact factor: 4.673

8.  A 35-year longitudinal assessment of cognition and midlife depression symptoms: the Vietnam Era Twin Study of Aging.

Authors:  Carol E Franz; Michael J Lyons; Robert O'Brien; Matthew S Panizzon; Kathleen Kim; Reshma Bhat; Michael D Grant; Rosemary Toomey; Seth Eisen; Hong Xian; William S Kremen
Journal:  Am J Geriatr Psychiatry       Date:  2011-06       Impact factor: 4.105

9.  The association between depressive mood and cognitive performance in an elderly general population - the MEMO Study.

Authors:  Bernhard T Baune; Thomas Suslow; Almut Engelien; Volker Arolt; Klaus Berger
Journal:  Dement Geriatr Cogn Disord       Date:  2006-06-01       Impact factor: 2.959

10.  Depression, apolipoprotein E genotype, and the incidence of mild cognitive impairment: a prospective cohort study.

Authors:  Yonas E Geda; David S Knopman; David A Mrazek; Gregory A Jicha; Glenn E Smith; Selamawit Negash; Bradley F Boeve; Robert J Ivnik; Ronald C Petersen; V Shane Pankratz; Walter A Rocca
Journal:  Arch Neurol       Date:  2006-03
View more
  13 in total

Review 1.  Cancer-related cognitive impairment: an update on state of the art, detection, and management strategies in cancer survivors.

Authors:  M Lange; F Joly; J Vardy; T Ahles; M Dubois; L Tron; G Winocur; M B De Ruiter; H Castel
Journal:  Ann Oncol       Date:  2019-12-01       Impact factor: 32.976

2.  A randomised wait-list controlled trial to evaluate Emotional Freedom Techniques for self-reported cancer-related cognitive impairment in cancer survivors (EMOTICON).

Authors:  Laura Tack; Tessa Lefebvre; Michelle Lycke; Chistine Langenaeken; Christel Fontaine; Marleen Borms; Marianne Hanssens; Christel Knops; Kathleen Meryck; Tom Boterberg; Hans Pottel; Patricia Schofield; Philip R Debruyne
Journal:  EClinicalMedicine       Date:  2021-08-19

Review 3.  The Impact of Endocrine Therapy on Cognitive Functions of Breast Cancer Patients: A Systematic Review.

Authors:  Ioannis Bakoyiannis; Eleousa-Alexandra Tsigka; Despina Perrea; Vasilios Pergialiotis
Journal:  Clin Drug Investig       Date:  2016-02       Impact factor: 2.859

4.  Negative Affect Is Associated With Higher Risk of Incident Cognitive Impairment in Nondepressed Postmenopausal Women.

Authors:  Laura E Korthauer; Joseph Goveas; Mark A Espeland; Sally A Shumaker; Katelyn R Garcia; Hilary Tindle; Elena Salmoirago-Blotcher; Kaycee M Sink; Leslie Vaughan; Stephen R Rapp; Susan M Resnick; Ira Driscoll
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2018-03-14       Impact factor: 6.053

5.  Depressive Symptoms Affect Working Memory in Healthy Older Adult Hispanics.

Authors:  Monica Salazar-Villanea; Edward Liebmann; Mauricio Garnier-Villarreal; Esteban Montenegro-Montenegro; David K Johnson
Journal:  J Depress Anxiety       Date:  2015-09-27

6.  The Role of Character Strengths in Depression: A Structural Equation Model.

Authors:  Ata Tehranchi; Hamid T Neshat Doost; Shole Amiri; Michael J Power
Journal:  Front Psychol       Date:  2018-09-06

7.  Validation of the Measurement of Need Frustration.

Authors:  Isabeau K Tindall; Guy J Curtis
Journal:  Front Psychol       Date:  2019-07-30

8.  The Psychometric Properties of the Center for Epidemiological Studies Depression Scale (CES-D) for Iranian Cancer Patients.

Authors:  Hamid Sharif Nia; Maryam Rezapour; Kelly A Allen; Saeed Pahlevan Sharif; Azar Jafari; Hojjat Torkmandi; Amir Hossein Goudarzian
Journal:  Asian Pac J Cancer Prev       Date:  2019-09-01

Review 9.  Long-Term Cognitive Dysfunction in Cancer Survivors.

Authors:  Zuzana Országhová; Michal Mego; Michal Chovanec
Journal:  Front Mol Biosci       Date:  2021-12-14

10.  Network analysis of depressive and anxiety symptoms in adolescents during and after the COVID-19 outbreak peak.

Authors:  Rui Liu; Xu Chen; Han Qi; Yuan Feng; Zhaohui Su; Teris Cheung; Todd Jackson; Hui Lei; Ling Zhang; Yu-Tao Xiang
Journal:  J Affect Disord       Date:  2022-01-04       Impact factor: 4.839

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.